Corcept Therapeutics Incorporated (CORT)

NASDAQ
21.49
-0.97(-4.32%)
After Hours
21.49
-0.01(-0.05%)
- Real-time Data
  • Volume:
    468,987
  • Bid/Ask:
    21.02/23.62
  • Day's Range:
    21.41 - 22.60

CORT Overview

Prev. Close
22.46
Day's Range
21.41-22.6
Revenue
352.89M
Open
22.22
52 wk Range
17.57-31.14
EPS
0.84
Volume
468,987
Market Cap
2.48B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
604,769
P/E Ratio
26.77
Beta
0.66
1-Year Change
-6.52%
Shares Outstanding
115,460,415
Next Earnings Date
Feb 24, 2022
What is your sentiment on Corcept Therapeutics Incorporated?
or
Market is currently closed. Voting is open during market hours.

Corcept Therapeutics Incorporated Company Profile

Employees
236

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellSellSell
SummaryStrong SellStrong SellStrong SellSellNeutral
  • bullish?
    0
    • Yes, I was right :-)
      0
  • Cort seems to be doing alright now while other biotechs got spooked by the Gilead news. Anyone know why that is?
    0
    • Shooting up like a rocket this morning. I'm not complaining, but seriously: what gives?
      0
  • Lol it lost 5% in one second what happened?
    0
    • 10%*
      0
  • Doesn't make any sense.. Cort had a record quarter. Their best quarter ever
    0
    • Hope we beat on earnings tomorrow
      1
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.